Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tert-Butyl Formate SCHEMBL27653282 | 0.89 | TDP1 (0.46) | TDP1 | |
| Tert-Butyl Formate SCHEMBL28328144 | 0.85 | TDP1 (0.50) | TDP1 | |
| Tert-Butyl Formate SCHEMBL17956858 | 0.82 | TDP1 (0.52) | TDP1 | |
| Tert-Butyl Formate SCHEMBL28092409 | 0.82 | TDP1 (0.56) | TDP1 | |
| Tert-Butyl Formate SCHEMBL28092916 | 0.81 | TDP1 (0.68) | TDP1 | |
| Tert-Butyl Formate SCHEMBL28331255 | 0.81 | TDP1 (0.68) | TDP1 | |
| Tert-Butyl Formate SCHEMBL27473155 | 0.81 | TDP1 (0.68) | TDP1 | |
| Formic Acid Methyl Ester SCHEMBL28546740 | 0.79 | — | — | |
| Tert-Butyl Formate SCHEMBL28873271 | 0.79 | TDP1 (0.48) | TDP1 | |
| Tert-Butyl Formate SCHEMBL27606011 | 0.79 | TDP1 (0.65) | TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110511209-A | It can be used as the indole carboxamides compound of kinase inhibitor | BRISTOL MYERS SQUIBB CO | 2019-11-29 | — | — | CN | disclosed |
| CN-106946867-B | FXR receptor modulators and its preparation method and application | 广州市恒诺康医药科技有限公司 | 2019-11-12 | — | — | CN | disclosed |
| CN-104583196-B | The method that 1,4-dibasic pyridazine analog and treatment lack relevant disease to SMN | 诺华股份有限公司 | 2016-10-12 | — | — | CN | disclosed |
| CN-104080787-B | Pyrazolo pyrrolidine compound | 诺华股份有限公司 | 2016-09-14 | — | — | CN | disclosed |
| CN-105612153-A | Substituted sulfonamide compounds as TRPA1 conditioner | HOFFMANN LA ROCHE | 2016-05-25 | — | — | CN | disclosed |
| CN-103391936-B | Carcinostatic agent | THE UNIVERSITY OF TOKYO (JP) | 2016-04-27 | — | — | CN | disclosed |
| CN-103635456-B | Tigecycline derivatives | KBP BIOSCIENCES Co.,Ltd. (CN) | 2016-03-09 | — | — | CN | disclosed |
| CN-105246888-A | Imidazopyridine compounds and uses thereof | TECHNOLOGY SG L P | 2016-01-13 | — | — | CN | disclosed |
| CN-105121425-A | Therapeutic compounds and compositions | AGIOS PHARMACEUTICALS INC | 2015-12-02 | — | — | CN | disclosed |
| CN-105121426-A | Pyrrolidine GPR40 modulators | BRISTOL MYERS SQUIBB CO | 2015-12-02 | — | — | CN | disclosed |
| CN-102203093-B | Aminotriazolopyridines and their use as kinase inhibitors | SIGNAL PHARM LLC | 2015-05-13 | — | — | CN | disclosed |
| CN-104583196-A | 1,4-disubstituted pyridazine analogs and methods for treating SMN-deficiency-related conditions | NOVARTIS AG | 2015-04-29 | — | — | CN | disclosed |
| CN-104080787-A | Pyrazolopyrrolidine compounds | NOVARTIS AG | 2014-10-01 | — | — | CN | disclosed |
| CN-104059066-A | Diazacarbazoles And Methods Of Use | GENENTECH INC | 2014-09-24 | — | — | CN | disclosed |
| CN-103391936-A | Anticancer agent | NAT UNIV CORP UNIV TOKYO | 2013-11-13 | — | — | CN | disclosed |
| CN-102892766-A | Kinase inhibitors and method of treating cancer with same | UNIV HEALTH NETWORK | 2013-01-23 | — | — | CN | disclosed |
| CN-102548984-A | Inhibitors of PI3 kinase and / or MTOR | AMGEN INC | 2012-07-04 | — | — | CN | disclosed |
| CN-102203093-A | Aminotriazolopyridines and their use as kinase inhibitors | SIGNAL PHARM LLC | 2011-09-28 | — | — | CN | disclosed |
| CN-102119163-A | Diazacarbazoles and methods of use | GENENTECH INC | 2011-07-06 | — | — | CN | disclosed |
| CN-1886392-A | Novel benzofuran derivatives, which can be used in prophylaxis or treatment of 5-ht6 receptor-related disorder | BIOVITRUM AKTIEBOLAG (SE) | 2006-12-27 | — | — | CN | disclosed |